Northwest Biotherapeutics signs Synteract to manage phase 2 trial of DCVax-Brain

By Lisa Kerner

Charlotte, N.C., Aug. 15 - Northwest Biotherapeutics, Inc. awarded a clinical trial management contract to Synteract to manage its phase 2 trial evaluating DCVax-Brain in patients with Glioblastoma multiforme.

DCVax-Brain uses the patient's own dendritic cells (immune cells) with the patient's own tumor biomarkers (antigens), according to a company news release.

The phase 2 trial is based on two phase 1 clinical trials that demonstrated that patient survival was more than twice as long for patients receiving DCVax-Brain treatment compared to two current Food and Drug Administration-approved therapies.

Northwest is a Bothell, Wash., biotechnology company focused on immunotherapy products for the treatment of cancer.

Synteract is a privately held, contract research organization based in Carlsbad, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.